Latest Research Collaboration News

Starpharma has confirmed FDA alignment for its DEP® HER2 first-in-human phase 1 trial, with preparations underway for a mid-2026 start. The biotech also progressed strategic partnerships, published promising data with Genentech, and reported a $14.1 million cash balance alongside rising Viraleze™ sales.

Neurotech International has opened its first Phase 3 clinical site for NTI164 targeting Autism Spectrum Disorder, reported positive 90-day toxicology results, and launched a new Rett syndrome research collaboration.

Paradigm Biopharmaceuticals has upsized a $14 million placement and launched a $2 million SPP, boosting its cash runway to around $45 million. This capital injection supports the ongoing Phase 3 trial for knee osteoarthritis, with interim results expected in Q3 2026.

Pure Resources has launched a cutting-edge research collaboration with Rice University to develop carbon nanotube fibre thermal management systems, leveraging graphite from its Garnet Hills Project. The initiative is backed by a $3 million equity raise to fund exploration and downstream material innovation.

Heavy Rare Earths Limited has confirmed the presence of valuable rare earth minerals Monazite and Xenotime at its Radium Hill Project, signalling new potential beyond historic uranium mining.

BPH Global is expanding its seaweed biomass research to develop renewable biofuels like biohydrogen and biocrude, aiming to carve out a sustainable alternative to fossil fuels in energy and transport sectors.

Neurotech International reports a dramatic reduction in half-year losses alongside significant clinical and regulatory progress for its lead cannabinoid therapy NTI164. The company also strengthens its cash position through a $4 million placement and a $4.7 million R&D tax refund.

Prescient Therapeutics reported a 62.8% increase in half-year losses to nearly $4 million, driven by intensified clinical development of its PTX-100 cancer therapy. The company bolstered its balance sheet with a $9.85 million capital raise while securing key regulatory milestones in Europe and the US.

Invex Therapeutics reports a net loss of $715,582 for H1 2026 while advancing its Exenatide program targeting neurological diseases, alongside notable board reshuffles.

Noxopharm Limited has secured a major scientific milestone with the publication of its Sofra™ platform research in Nature Immunology, highlighting a novel anti-inflammatory mechanism with broad therapeutic potential.

Critical Resources Limited has secured a strategic position within the US Centre for Solid-State Electric Power Storage, accelerating its evaluation and development of safer, higher-performance solid-state lithium-ion batteries.

HITIQ has made significant strides in expanding its concussion management technology, PROTEQT©, into North America and Australian retail, backed by strong research partnerships and a successful capital raise.